Please see full Prescribing Information, including Patient Information, for ANORO ELLIPTA.
Please see full Prescribing Information, including Patient Information, for TRELEGY ELLIPTA.

INDICATIONS
  • COPD: ANORO and TRELEGY 100/62.5/25 mcg are for maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
  • Asthma: TRELEGY is for maintenance treatment of asthma in patients aged 18 years and older.
Limitations of Use: ANORO and TRELEGY are NOT indicated for relief of acute bronchospasm. ANORO is NOT indicated for asthma.

IMPORTANT SAFETY INFORMATION FOR ANORO AND TRELEGY

CONTRAINDICATIONS

  • TRELEGY is contraindicated in the primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required.
  • ANORO and TRELEGY are contraindicated in patients with severe hypersensitivity to milk proteins or demonstrated hypersensitivity to any of the active ingredients or excipients.
  • Use of a long-acting beta2-adrenergic agonist (LABA), including ANORO, without an inhaled corticosteroid (ICS) is contraindicated in patients with asthma.

WARNINGS AND PRECAUTIONS

  • ANORO is not for the treatment of asthma. LABA monotherapy (without ICS) for asthma increases the risk of asthma-related death, and in pediatric and adolescent patients, available data also suggest an increased risk of asthma-related hospitalization. These findings are considered a class effect of LABA monotherapy. When LABA are used with ICS in fixed-dose combination, as in TRELEGY, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone. Available data do not suggest an increased risk of death with use of LABA in patients with COPD. ANORO and TRELEGY are not indicated for use in pediatric patients aged 17 years and younger.
  • ANORO and TRELEGY should NOT be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of COPD or asthma.
  • ANORO and TRELEGY are NOT rescue medications and should NOT be used for the relief of acute bronchospasm or symptoms. Acute symptoms should be treated with an inhaled, short-acting beta2-agonist.
  • ANORO and TRELEGY should not be used more often or at higher doses than recommended or with another LABA for any reason, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs, like LABA.
  • Oropharyngeal candidiasis has occurred in patients treated with orally inhaled drug products containing fluticasone furoate. Advise patients taking TRELEGY to rinse their mouths with water without swallowing after inhalation.
  • Lower respiratory tract infections, including pneumonia, have been reported following use of ICS, like fluticasone furoate, in TRELEGY. Physicians should remain vigilant for the possible development of pneumonia in patients with COPD, as clinical features of pneumonia and exacerbations frequently overlap.
  • A more serious or even fatal course of chickenpox or measles may occur in susceptible patients using corticosteroids. ICS-containing products, like TRELEGY, should be used with caution, if at all, in patients with active or quiescent tuberculosis infections of the respiratory tract; systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.
  • Particular care is needed for patients transferred from systemic corticosteroids to ICS because deaths due to adrenal insufficiency have occurred in patients during and after transfer. Taper patients slowly from systemic corticosteroids if transferring to TRELEGY.
  • Hypercorticism and adrenal suppression may occur with higher than the recommended dosage or at the regular dosage of ICS in susceptible individuals. If such changes occur, reduce the dose of TRELEGY slowly and consider other treatments for management of COPD or asthma symptoms.
  • Caution should be exercised when considering the coadministration of ANORO or TRELEGY with ketoconazole and other known strong CYP3A4 inhibitors (including, but not limited to, ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, voriconazole) because increased systemic corticosteroid and cardiovascular adverse effects may occur.
  • If paradoxical bronchospasm occurs, discontinue ANORO or TRELEGY and institute alternative therapy.
  • Hypersensitivity reactions such as anaphylaxis, angioedema, rash, and urticaria may occur after administration of ANORO or TRELEGY. Discontinue ANORO or TRELEGY if such reactions occur.
  • Vilanterol can produce clinically significant cardiovascular effects in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and also cardiac arrhythmias, such as supraventricular tachycardia and extrasystoles. If such effects occur, ANORO or TRELEGY may need to be discontinued. ANORO or TRELEGY should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.
  • Decreases in bone mineral density have been observed with long‐term administration of products containing ICS, like TRELEGY. Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (eg, anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care prior to initiating TRELEGY and periodically thereafter.
  • Use ANORO or TRELEGY with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis, and in patients who are unusually responsive to sympathomimetic amines.
  • Glaucoma, increased intraocular pressure, and cataracts have been reported following the long‐term administration of products containing ICS like TRELEGY or products containing inhaled anticholinergics like TRELEGY. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use TRELEGY long term.
  • Use ANORO or TRELEGY with caution in patients with narrow-angle glaucoma. Instruct patients to contact a healthcare provider immediately if signs or symptoms of acute narrow-angle glaucoma develop.
  • Use ANORO or TRELEGY with caution in patients with urinary retention, especially in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to contact a healthcare provider immediately if signs or symptoms of urinary retention develop.
  • Be alert to hypokalemia and hyperglycemia with patients taking ANORO or TRELEGY.
  • Orally inhaled corticosteroids, like TRELEGY, may reduce growth velocity in children and adolescents.

ADVERSE REACTIONS

ANORO FOR COPD

  • The most common adverse reactions (≥1% and more common than placebo) reported in four 6-month clinical trials with ANORO (and placebo) were: pharyngitis, 2% (<1%); sinusitis, 1% (<1%); lower respiratory tract infection, 1% (<1%); constipation, 1% (<1%); diarrhea, 2% (1%); pain in extremity, 2% (1%); muscle spasms, 1% (<1%); neck pain, 1% (<1%); and chest pain, 1% (<1%).


TRELEGY 100/62.5/25 MCG FOR COPD

  • In subjects with COPD, the most common adverse reactions (≥1% and more common than placebo + fluticasone furoate/vilanterol [FF/VI]) reported in two 12-week clinical trials with umeclidinium + FF/VI, the components of TRELEGY, (and placebo + FF/VI) were: headache, 4% (3%); back pain, 4% (2%); dysgeusia, 2% (<1%); diarrhea, 2% (<1%); cough, 1% (<1%); oropharyngeal pain, 1% (0%); and gastroenteritis, 1% (0%).
  • Additional adverse reactions (≥1% incidence) reported in subjects with COPD taking TRELEGY in a 52-week trial included upper respiratory tract infection, pneumonia, bronchitis, oral candidiasis, arthralgia, influenza, sinusitis, pharyngitis, rhinitis, constipation, urinary tract infection, and dysphonia.


TRELEGY FOR ASTHMA

  • In subjects with asthma, the most common adverse reactions (≥2% incidence with TRELEGY) reported in a 24-week to 52-week clinical trial with:
  • -TRELEGY 100/62.5/25 mcg (or FF/VI 100/25 mcg) were: pharyngitis/nasopharyngitis, 17% (16%); headache, 9% (7%); upper respiratory tract infection/viral upper respiratory tract infection, 5% (7%); respiratory tract infection/viral respiratory tract infection, 4% (4%); bronchitis, 4% (3%); influenza, 4% (3%); back pain, 3% (4%); sinusitis/acute sinusitis, 2% (3%); rhinitis, 2% (3%).
    -TRELEGY 200/62.5/25 mcg (or FF/VI 200/25 mcg) were: pharyngitis/nasopharyngitis, 15% (16%); upper respiratory tract infection/viral upper respiratory tract infection, 7% (6%); headache, 5% (6%); bronchitis, 5% (5%); sinusitis/acute sinusitis, 3% (2%); respiratory tract infection/viral respiratory tract infection, 3% (2%); back pain, 2% (1%); urinary tract infection, 2% (<1%).

DRUG INTERACTIONS

  • ANORO and TRELEGY should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval, or within 2 weeks of discontinuation of such agents, because they may potentiate the effect of vilanterol on the cardiovascular system.
  • Use beta‐blockers with caution, as they not only block the pulmonary effect of beta‐agonists, such as vilanterol, but may produce severe bronchospasm in patients with COPD or asthma.
  • Use ANORO or TRELEGY with caution in patients taking non–potassium-sparing diuretics, as ECG changes and/or hypokalemia associated with these diuretics may worsen with concomitant beta-agonists.
  • Avoid coadministration of ANORO or TRELEGY with other anticholinergic-containing drugs, as this may lead to an increase in anticholinergic adverse effects.

Loading your events...

Register for the selected events

To report SUSPECTED ADVERSE REACTIONS, contact GSK at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
This site is intended for US healthcare professionals only.

ANORO ELLIPTA and TRELEGY ELLIPTA were developed in collaboration with
 

 

Trademarks are owned by or licensed to the GSK group of companies.

©2020 GSK or licensor.
UCVWCNT200042 October 2020
Produced in USA.

Thank you for registering!

In the next few minutes, you should receive a confirmation email with your login information for each event you selected. If you do not receive a confirmation email in 15 minutes, please email support.